Botulinum toxin and nerve activity in hidradenitis suppurativa skin inflammation
Studies whether botulinum toxin lowers skin inflammation in people with hidradenitis suppurativa.
Key facts
- Who runs it
- University of Massachusetts, Worcester
- Where
- Worcester, United StatesSee the site
- Trial code
- Registry title
- Targeting Nociceptors in Hidradenitis Suppurativa
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 7 Jun 2022
- Expected to end
- 30 Apr 2028
- Type of study
- Observational
- Treatments tested
- Botulinum toxin
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hidradenitis suppurativa (HS), a long-lasting inflammatory skin disease. It tests whether botulinum toxin reduces skin inflammation.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- A confirmed diagnosis of HS. HS skin lesions for at least 1 year, in at least two different body areas.
Main reasons for not taking part
- Pregnant or breastfeeding
- A nerve and muscle disorder, such as ALS, myasthenia gravis, Lambert-Eaton syndrome or myopathy
- A health problem that makes a skin biopsy risky, such as end stage heart failure or a blood clotting problem
- An active bacterial, fungal or viral infection in the treatment area
- Known allergy to botulinum toxin A products or their parts (human albumin, saline, lactose, sodium succinate)
The registry criteria, word for word
Show all 11 criteriaShow less
Other criteria
- Inclusion:
- Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
- HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas; Exclusion:
- Age < 18 years or > 75 years
- pregnant or breastfeeding
- neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy)
- medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy)
- active bacterial, fungal, or viral infection in the treatment area
- known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate)
- prisoners
- adults unable to consent for themselves
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of Massachusetts Chan Medical SchoolWorcester, United StatesContact: Sidney Leno, MDTaking people
About the trial
What the trial wants to find out
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
The group in the trial
- single group assignment
men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa
Treatment: Botulinum toxin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Targeting Nociceptors in Hidradenitis Suppurativa
- Plain-language title
- Botulinum toxin and nerve activity in hidradenitis suppurativa skin inflammationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05403710, who can take part
- Record updated
- 10 September 2026